Efficacy of erenumab and factors predicting response after 3 months in treatment resistant chronic migraine: a clinical service evaluation

BACKGROUND: Calcitonin gene-related peptide (CGRP) inhibitors have been developed as options for treatment of chronic and episodic migraine. We present our experience of the use of erenumab in a tertiary headache centre. METHODS: This was a prospective clinical audit of all patients commenced on ere...

Descripción completa

Detalles Bibliográficos
Autores principales: Lowe, Michael, Murray, Lesley, Tyagi, Alok, Gorrie, George, Miller, Sarah, Dani, Krishna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Milan 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306036/
https://www.ncbi.nlm.nih.gov/pubmed/35869443
http://dx.doi.org/10.1186/s10194-022-01456-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306036/
https://www.ncbi.nlm.nih.gov/pubmed/35869443
http://dx.doi.org/10.1186/s10194-022-01456-2

Ejemplares similares